Here are the 424B prospectus supplements from PolyPid Ltd. (PYPD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PYPD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PYPD filings page.
PolyPid Ltd. (PYPD) is increasing its at-the-market share offering program to a maximum aggregate offering price of up to $15,000,000 of ordinary shares under its Form F-3 shelf. This prospectus supplement raises the prior cap of $8,250,000 and continues the sales agreement with Oppenheimer & Co. Inc. as sales agent on a best efforts basis. Oppenheimer will receive a 3.0% commission on the gross sales price per share and reimbursement of up to $40,000 of specified expenses.
The company’s ordinary shares trade on Nasdaq under the symbol PYPD; the last reported sale price was $3.68 per share on November 25, 2025. The aggregate market value of ordinary shares held by non-affiliates was $65,953,832 as of October 30, 2025, based on 17,175,477 non-affiliate shares at $3.84 per share.